CNBC’s “Fast Money” team discusses new obesity drug data and the market leaders, including Novo Nordisk and Eli Lilly, with Dr. Kavita Patel, NBC News and MSNBC medical contributor.
Breakdown
- Novo Nordisk's new data on obesity treatments is generating positive attention. 49s
- Cost, side effects, and medication adherence are major factors for prescribers. 1m 2s
- Companies are developing different formulations and dosing to meet varied patient needs. 1m 28s
- Patients are adjusting doses to balance weight loss goals and side effects. 2m 8s
- Muscle loss with significant fat loss is a concern being addressed in ongoing trials. 2m 27s